SPOTLIGHT: CV's Ranexa wins FDA review

CV Therapeutics is making progress in its pursuit of new indications for Ranexa, its angina drug for patients who haven't responded to other therapies. The agency agreed to consider its application to approve Ranexa for cardiac arrhythmia. The agency already has Ranexa under review as a front-line therapy for angina and will consider a label change noting that the therapy reduces the level of glucose in the blood of coronary artery disease patients with diabetes. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.